Quantcast

Latest Nebulizer Stories

2009-09-10 07:30:00

SAN DIEGO, Sept. 10 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced positive data from its Phase 2b clinical trial with Aeroquin((R)) (a novel aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF). Trial results showed that nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa (P. aeruginosa) in sputum after 28 days of dosing versus placebo. Clinically and statistically significant improvements versus placebo were...

2009-07-30 07:36:00

MONMOUTH JUNCTION, N.J., July 30 /PRNewswire/ -- Transave Inc. announced today that it has entered into a cooperative research and development agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study ARIKACE(TM) (liposomal amikacin for inhalation) in patients with nontuberculous mycobacteria (NTM) lung infections. Transave and NIAID will collaborate on the planning, design and implementation of a clinical...

2009-07-21 08:00:00

MIDLOTHIAN, Va., July 21 /PRNewswire/ -- Today, PARI Respiratory Equipment was granted a US Patent for its Vortex Holding Chamber, a unique, non-electrostatic, holding chamber with a one piece, dual-valve system that optimizes patient inhalation and exhalation for more efficient medication delivery with a metered dose inhaler (MDI). "While metered dose inhalers offer a quick burst of medication, there are a number of problems delivering an effective dose to patients. These include...

2009-06-30 11:53:00

MIDLOTHIAN, Va., June 30 /PRNewswire/ -- In two recent COPD studies sponsored by DEY LP, PARI's LC Plus nebulizer and PRONEB compressors (Ultra and Ultra II) were used to show that nebulized formoterol fumarate (Perforomist, DEY LP, Mylan Inc.) improves pulmonary function. "We are pleased that researchers chose PARI products as the exclusive nebulizer systems for recent studies comparing maintenance treatments for COPD. Sutherland et al. used an open-label crossover design allowing...

2009-06-25 08:45:00

Company Also Receives Patent Covering ARIKACE for Once-Daily Treatment of Pseudomonas Lung Infections MONMOUTH JUNCTION, N.J., June 25 /PRNewswire/ -- Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, has provided a $2.2 million award to Transave Inc., for the continued development of ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat Pseudomonas lung infections in cystic fibrosis (CF) and non-CF...

2009-06-02 15:08:00

MONTEREY, Calif., June 2 /PRNewswire/ -- This month's Journal of Aerosol Medicine and Pulmonary Drug Delivery features positive Phase Ib clinical trial results for PARI Pharma's L-CsA, inhaled liposomal cyclosporine A. In May, PARI Pharma received Orphan Drug Designation from the Food and Drug Administration for L-CsA, delivered via an Investigational eFlow Nebulizer System, for the prevention and treatment of bronchiolitis obliterans, a devastating, incurable disease of the small airways...

2009-05-20 14:26:00

Positive Results Based on New DSCG Formulation & eFlow Technology Delivery MUNICH and MONTEREY, Calif., May 20 /PRNewswire/ -- This week, Swiss researchers presented positive data from an ongoing Phase II clinical study at the American Thoracic Society (ATS) International Conference that compared PARI Pharma's inhaled IsoCrom, an isotonic 1% disodium cromoglycate (DSCG) solution, to inhaled corticosteroids (ICS) in 28 children with atopic asthma. Results showed decreases in mean asthma...

2009-05-07 10:00:00

MUNICH and MONTEREY, Calif., May 7 /PRNewswire/ -- PARI Pharma GmbH received an Orphan Drug Designation (ODD) by the European Commission based on a positive recommendation by the EMEA for inhaled PARI Tobramycin 100 delivered via a customized Investigational eFlow Nebulizer System. This is the second ODD designation that PARI Pharma has received for a product in its proprietary drug pipeline; the first ODD was granted for PARI's inhaled cyclosporine delivered via an eFlow Technology device....

2009-04-21 09:00:00

Presently No Approved Treatments MONMOUTH JUNCTION, N.J., April 21 /PRNewswire/ -- Transave, Inc., today reported completion of patient enrollment in a Phase II study evaluating the safety and efficacy of Arikace(TM) (liposomal amikacin for inhalation) in non-cystic fibrosis (CF) bronchiectasis patients. The results, which are expected to be available by mid-year, will shed new light on how this patient population responds to treatment. Presently, there are no approved treatments for the...

2009-03-30 08:00:00

MIDLOTHIAN, Va., March 30 /PRNewswire/ -- PARI Respiratory Equipment's LC Sprint reusable nebulizer and TREK S portable compressor were both used in the filming of the final episode of "ER" that will air Thursday at 9pm on NBC. Numerous stars are reprising roles for the final season of "ER," including George Clooney and Julianna Margulies, so the return of PARI products goes hand in hand - as PARI nebulizers have been used on the show to highlight treatments for a variety of respiratory...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.